Trials / Completed
CompletedNCT01808092
A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia
A Phase III, Randomized, Multicentre, Double-blind, Double-dummy, Parallel-group Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam Versus Meropenem in the Treatment of Nosocomial Pneumonia Including Ventilator-Associated Pneumonia in Hospitalized Adults
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 969 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the effects of Ceftazidime-Avibactam compared to Meropenem for treating hospitalized adults with nosocomial pneumonia including ventilator-associated pneumonia
Detailed description
A Phase III, Randomized, Multicentre, Double-blind, Double-dummy, Parallel-group Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam Versus Meropenem in the Treatment of Nosocomial Pneumonia Including Ventilator-Associated Pneumonia in Hospitalized Adults
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ceftazidim-avibactam (CAZ-AVI, experimental product) | 2000mg ceftazidime plus 500mg avibactam |
| DRUG | meropenem (active comparator) | 1000mg of Meropenem |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2013-03-11
- Last updated
- 2017-09-06
- Results posted
- 2017-02-03
Locations
123 sites across 26 countries: Argentina, Brazil, Bulgaria, China, Czechia, France, Hungary, India, Italy, Japan, Latvia, Mexico, Peru, Philippines, Poland, Romania, Russia, Slovenia, South Africa, South Korea, Spain, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom, Vietnam
Source: ClinicalTrials.gov record NCT01808092. Inclusion in this directory is not an endorsement.